Adaptive Biotechnologies Receives $195,000,000 New Financing

  • Feed Type
  • Date
    5/6/2015
  • Company Name
    Adaptive Biotechnologies
  • Mailing Address
    1551 Eastlake Avenue East Seattle, WA 98102 USA
  • Company Description
    Adaptive Biotechnologies’ platform technology breaks open the field of genomics immunology. T-cell receptor profiling using Adaptive’s proprietary technology and software allows scientists to study the adaptive immune system to an unprecedented depth via high-throughput T-Cell Receptor (TCR) sequencing.
  • Website
    http://www.adaptivebiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $195,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    This investment will fuel significant expansion of the Company’s research platform, support the commercialization of a novel target identification technology for T-cell therapy, and expedite global regulatory submissions and launch timelines for its research-use-only and clinical diagnostic products. Additionally, funds will be allocated to support the continued growth of the world’s largest database of adaptive immune receptors to inform future diagnostic and therapeutic discoveries across disease states.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy